Immuneering Corporation (IMRX) is experiencing a decline in its stock price, down 7.19% to $2.58 as of 9:37 am on September 18, after opening at $2.66. The stock has seen a high of $2.66 and a low of $2.50 during today's trading session. Despite the recent positive momentum driven by promising efficacy data from its pancreatic cancer study, which had propelled the stock up by over 94% since September 13, IMRX is now facing a pullback. The stock's current overbought status, with a 14-day Relative Strength Index (RSI) of 85.2, suggests that it may be experiencing a natural correction as investors take profits. On Reddit, discussions continue to focus on potential buy signals, with one user highlighting an 87% win rate on a 15-minute chart, indicating ongoing interest from retail traders.